Abstract
Emphasis on the use of small specimens for biomarker testing to provide prognostic and predictive information for guiding clinical management for patients with advanced-stage cancer has been increasing. These biomarker tests include molecular analysis, cytogenetic tests, and immunohistochemical assays. Owing to the limited nature of the cellular material procured in these small specimens, which are collected using minimally invasive techniques (ie, fine needle aspiration and core needle biopsy), pathologists have been required to triage these samples judiciously and provide the clinically relevant genomic information required for patient care. Awareness of the advantages and limitations of these specimen preparations and the specific preanalytic requirements for the testing methods will help pathologists to develop optimal strategies to maximize the chances of effectively using these samples for comprehensive diagnostic and relevant biomarker testing.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 450-460 |
| Number of pages | 11 |
| Journal | Journal of the American Society of Cytopathology |
| Volume | 9 |
| Issue number | 5 |
| DOIs | |
| State | Published - Sep 1 2020 |
Keywords
- Biomarker
- Biopsy
- Core needle
- Cytology
- Fine needle
- Molecular
- Small specimen
ASJC Scopus subject areas
- Pathology and Forensic Medicine